Long-term PPI use linked to increased fracture risk
This article was originally published in Scrip
Long-term use of proton-pump inhibitors (PPIs) is associated with an increased risk of fracture, suggests a retrospective study of 15,792 individuals over age 50 who had osteoporosis-related fractures of the hip, vertebra or wrist.
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
Gilead Scienceswill need to conduct another clinical trial of its investigational cystic fibrosis treatment aztreonam lysine for inhalation before the drug can be approved, the US FDAhas said.